Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Royal Bank of Canada — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.13 (market cap $29.60B), while Royal Bank of Canada trades at $211.48 (market cap $292.32B). The key difference: Royal Bank of Canada is far larger — about 9.9× Alnylam Pharmaceuticals, Inc.'s market cap, and Royal Bank of Canada pays a 2.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RY | |
|---|---|---|
Market Cap | $29.60B | $292.32B |
Sector | Health | Financials |
52-Week High | $491.22 | $217.87 |
52-Week Low | $205.48 | $134.80 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Royal Bank of Canada (RY) trades at $210.79, down slightly by 0.14% today. The stock shows a bullish technical trend with strong earnings performance, beating EPS estimates in three consecutive quarters. Revenue grew to $66.53 billion in 2025, with a net income margin of 31.85%. Analyst sentiment is mixed with a Buy consensus of 43% but a majority Hold rating. Recent insider selling and a dividend announcement highlight corporate activity.
RY presents a stable investment with solid profitability and dividend yield, but faces risks from high valuation multiples and macroeconomic sensitivity. Upside is supported by earnings growth and institutional holdings, while insider sales and debt levels warrant caution. The stock remains a core holding for dividend-focused portfolios amid moderate growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
